Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study | Zendy

Akihiko Takahashi | Zendy; Hiroyuki Takase | Zendy; Takayuki Toriyama | Zendy; Tomonori Sugiura | Zendy; Yutaka KURITA | Zendy; Ryuzo Ueda | Zendy; Yasuaki Dohi | Zendy

Open Access

Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study

Author(s) -

Akihiko Takahashi,

Hiroyuki Takase,

Takayuki Toriyama,

Tomonori Sugiura,

Yutaka KURITA,

Ryuzo Ueda,

Yasuaki Dohi

Publication year - 2006

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfl293

Subject(s) - candesartan , medicine , cardiology , heart failure , myocardial infarction , clinical endpoint , angiotensin ii , angiotensin receptor , randomized controlled trial , blood pressure

Cardiovascular events are the major determinants of the prognosis of patients on chronic haemodialysis. The present study was designed to investigate whether candesartan, an angiotensin II type-1 receptor blocker, reduces the incidence of cardiovascular events in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research